undamentalytics Newsletter
Sign in

Protalix Biotherapeutics, Inc. (PLX) stock

Add to watchlist

Add holding +

NYSE: PLX NYSE Biotechnology Next results ~November 12, 2026

B+ Fundamentals grade

Protalix Biotherapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$3.6

Valuation models combined (2)

Base case. Range ~$2.2–$6.5. Weighted average of 2 models (price-to-earnings vs peers, revenue-to-maturity model), the price-to-earnings vs peers counting double.

Price vs value

No Buy/Hold/Sell rating is issued: only 2 valuation models apply; a rating needs 3.

Protalix Biotherapeutics, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 1 selling1 purchase and 1 sale by directors and officers, last 12 monthsInsider trades
  • Funds57 adding, 33 cuttingOf 15 active managers that changed their stake, 12 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Protalix Biotherapeutics files

Where Protalix Biotherapeutics stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $81m, up 30.1% on a year earlier, faster than the 27.8% growth a quarter earlier. Free-cash-flow margin rose to 9.5% from -5.6% a year earlier. Operating margin widened to 28.9% from 13.3%. The diluted share count is down 4.1% on a year earlier, which lifts each remaining share. Against its peers on growth, profitability, cash generation and balance sheet, it grades B+. It passes 2 of our 2 financial-health checks. Our valuation models combined value is $5.11 a share, against a share price of $2.63.

Source: 10-Q filed August 12, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 12, 2026 (estimated)

Protalix Biotherapeutics, Inc.'s trailing-twelve-month revenue grew 30.1% year on year, with a free-cash-flow margin of 9.5%. Where it stands out: change in share count of -4.1% ranks 6 of 156 biotechnology companies we cover.

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 600% in the quarter to 2026-06-30, the 2nd beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 30.1% over the last 12 months, against a median of 12.6% for biotechnology companies we cover.
  • High operating margin. 28.9% of revenue is left as operating profit, against a median of -189.4% for biotechnology companies we cover.
  • Margins widening. Operating margin is up 15.6 points on a year ago.
  • Shrinking share count. Diluted shares fell 4.1% in a year, so each share owns more of the business.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Results due soon. Results are expected around 12 November; the share price can move sharply on the day.
  • Volatile shares. Over the past year the shares showed annualised volatility of 54% and a beta of 1.0 against the S&P 500.
  • Weak cash conversion. Free cash flow was 40% of net income over the last 12 months.
  • Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.
  • Earnings expected to fall. The consensus expects earnings per share to fall 79% next year.

Latest results: FY2026 Q2

Filed August 12, 2026
Earnings per share
$0.05 against an average estimate of -$0.01: beat by 600.0%
Revenue
$20m, up 27.1% on a year earlier
Share reaction
-2.9% in the first session after the results on August 12, 2026, against +0.9% for the S&P 500
Next report
November 12, 2026

Protalix Biotherapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-1.2%
  • 1 week+3.2%
  • 1 month-5.5%
  • This year+42.2%
  • 1 year+8.0%
  • 5 years+118.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$80.6M
Operating margin
28.9%
Net margin
23.5%
EPS (TTM, diluted)
$0.24

Growth

Revenue growth
+30.1%
Change in growth rate
+2.3 pts
Share count change
−4.1%

Cash

Free cash flow (TTM)
$7.7M
FCF margin
9.5%
Stock pay % of revenue
2.4%

Earnings

Last results
August 12, 2026
Next results (est.)
November 12, 2026

News & updates

Updated November 3, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Protalix Biotherapeutics, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 2 valuation models apply; a rating needs 3.

Valuation models

We value Protalix Biotherapeutics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9%: the 10-year Treasury yield (4.9%) plus a beta of 0.89 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. ~$2.2 ~$1.7–$5.0 Primary model, counts double
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$0.6 ~$0.4–$1.0 Left out: far from the other models (more than 3x away from their median)
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$0.5 ~$0.4–$0.6 Left out: out of range vs price (0.20x)
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$6.5 ~$5.4–$7.7 Included
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: earnings are positive: price-to-earnings is the better measure
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$3.6 ~$2.2–$6.5 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Protalix Biotherapeutics, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$10.20$4.50$6.60$3.10$3.28$3.63$0.83$1.37$1.78$1.88$1.80$2.56
Market value$194m$91m$173m$91m$97m$106m$37m$66m$147m$152m$141m$206m
+ Net debt (− = net cash)−$9m$10m$1m$10m$37m−$18m−$11m$11m$17m−$20m−$15m−$27m
Enterprise value$185m$101m$174m$101m$135m$88m$26m$77m$163m$133m$127m$179m
Multiples
Price / sales 44.4x9.9x8.2x2.7x1.8x1.7x1.0x1.4x2.2x2.9x2.7x2.6x
Price / earnings 3.3x———————17.7x52.0x—10.9x
Price / free cash flow —————————20.6x—26.9x
EV / EBITDA —————21.8x——14.0x25.4x—7.2x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

27 /100

Weak moat

How hard Protalix Biotherapeutics's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -17.6% of total assets over 10 years.

  • Pricing power 12 / 20

    Gross margin has been a median 65.6%, moving by 23.7 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median -29.6%; its worst year was -203.4%.

  • Cash conversion 1 / 20

    Free cash flow was positive in 1 of 10 years, at a median -24.0% of revenue.

  • Discipline 9 / 20

    The diluted share count rose 111.6% over five years; stock-based pay has been a median 2.8% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (32 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 12, 2026, before the open. Analysts expect revenue of $12m for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $0.24 +400% $82m +56%
Next $0.05 −79% $66m −19%

Next year's EPS estimate has moved 0.0% in 90 days, across 2 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +23.1% on 90 days ago. In the last 30 days, 2 analysts raised Protalix Biotherapeutics, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Protalix Biotherapeutics, Inc., last 90 days
$0.00 $0.10 $0.20 $0.30 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $0.20 Current fiscal year, 60 days ago: $0.20 Current fiscal year, 30 days ago: $0.20 Current fiscal year, 7 days ago: $0.19 Current fiscal year, Now: $0.24 $0.24 Next fiscal year, 90 days ago: $0.05 Next fiscal year, 60 days ago: $0.05 Next fiscal year, 30 days ago: $0.05 Next fiscal year, 7 days ago: $0.06 Next fiscal year, Now: $0.05 $0.05

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $0.20$0.05
60 days ago $0.20$0.05
30 days ago $0.20$0.05
7 days ago $0.19$0.06
Now $0.24$0.05

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.01 $0.05 +600.0%
Mar 2026 −$0.01 $0.22 +2300.0%
Dec 2025 $0.01 −$0.07 −1500.0%
Sept 2025 $0.06 $0.03 −45.5%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

1 analysts, Oct 2026
Buy1100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202611
  2. Sep 202611

Counts of recommendations published by analysts covering Protalix Biotherapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
4.5%
of tradable shares
Days to cover
3.96
at average volume
Short interest, 1 month
+22%
to October 15, 2026
Held by institutions
24%
of shares
Held by insiders
3.9%
of shares
Employees
226
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +8.0%

$2.37 on October 31, 2025 to $2.56

ThenNowEffect
Revenue (last 12 months) $62m $81m +30.1%
Net margin 10.1% 23.5% +132.0%
P/E multiple 31.7x 10.9x −65.7%
Share count 84m 80m +4.3%

Biggest factor: p/e multiple.

Last 3 years +38.4%

$1.85 on November 3, 2023 to $2.56

ThenNowEffect
Revenue (last 12 months) $67m $81m +19.5%
Net margin 13.2% 23.5% +78.1%
P/E multiple 12.5x 10.9x −13.3%
Share count 60m 80m −25.0%

Biggest factor: net margin.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
PLX−77%+65%+30%+6%−4%+42%
Industry peers (median)−35%−57%−18%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
PLX25%58%58%50%58%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
PLX−87%−36%−60%−51%−56%−40%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 3, 2015: 94% from March 14, 2017 to December 3, 2021. Getting back needed a 1678% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.67 – $3.15
From 52-week high
−18.7%
vs 50-day average
−3.3%
vs 200-day average
+5.9%
Volatility (1 year)
54%
Beta vs S&P 500
1.03

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 9 down
typical move ±13.8%
After a week
3 up, 9 down
typical move ±16.6%
After a month
6 up, 6 down
typical move ±18.4%
Results releasedNext dayS&P 500 next day5 days21 days
August 12, 2026 −2.9% +0.9% −3.3% +8.6%
May 13, 2026 +4.7% +1.4% +5.2% +9.4%
March 18, 2026 −20.1% −1.6% −22.6% −16.8%
November 13, 2025 −13.1% −1.7% −18.7% −18.7%
August 14, 2025 −8.1% −0.2% −1.9% +18.6%
May 9, 2025 −49.5% +3.2% −42.2% −45.3%
March 17, 2025 +4.9% −0.3% +16.1% +17.0%
November 14, 2024 +12.9% −1.9% +33.9% +41.1%
August 14, 2024 −8.7% +2.0% −6.7% +1.0%
May 10, 2024 −8.8% +0.1% −8.8% −5.6%
March 14, 2024 −12.5% −0.9% −13.2% −25.0%
November 6, 2023 −18.9% +0.5% −27.0% −14.1%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Protalix Biotherapeutics, Inc. in five measures

Fundamentals grade B+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Protalix Biotherapeutics, Inc.
$20M $40M $60M $80M $100M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $63.6M Revenue (TTM), FY23 Q4: $65.5M Revenue (TTM), FY24 Q1: $59.7M Revenue (TTM), FY24 Q2: $38.1M Revenue (TTM), FY24 Q3: $45.7M Revenue (TTM), FY24 Q4: $53.4M Revenue (TTM), FY25 Q1: $59.8M Revenue (TTM), FY25 Q2: $61.9M Revenue (TTM), FY25 Q3: $61.8M Revenue (TTM), FY25 Q4: $52.7M Revenue (TTM), FY26 Q1: $76.4M Revenue (TTM), FY26 Q2: $80.6M $80.6M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $63.6M
FY23 Q4 $65.5M
FY24 Q1 $59.7M
FY24 Q2 $38.1M
FY24 Q3 $45.7M
FY24 Q4 $53.4M
FY25 Q1 $59.8M
FY25 Q2 $61.9M
FY25 Q3 $61.8M
FY25 Q4 $52.7M
FY26 Q1 $76.4M
FY26 Q2 $80.6M
Revenue growth, TTM YoY Protalix Biotherapeutics, Inc.
-50% 0% 50% 100% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 33.8% Revenue growth, TTM YoY, FY23 Q4: 37.5% Revenue growth, TTM YoY, FY24 Q1: 45.0% Revenue growth, TTM YoY, FY24 Q2: -43.6% Revenue growth, TTM YoY, FY24 Q3: -28.2% Revenue growth, TTM YoY, FY24 Q4: -18.5% Revenue growth, TTM YoY, FY25 Q1: 0.2% Revenue growth, TTM YoY, FY25 Q2: 62.8% Revenue growth, TTM YoY, FY25 Q3: 35.4% Revenue growth, TTM YoY, FY25 Q4: -1.2% Revenue growth, TTM YoY, FY26 Q1: 27.8% Revenue growth, TTM YoY, FY26 Q2: 30.1% 30.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 33.8%
FY23 Q4 37.5%
FY24 Q1 45.0%
FY24 Q2 -43.6%
FY24 Q3 -28.2%
FY24 Q4 -18.5%
FY25 Q1 0.2%
FY25 Q2 62.8%
FY25 Q3 35.4%
FY25 Q4 -1.2%
FY26 Q1 27.8%
FY26 Q2 30.1%
Operating margin (TTM) Protalix Biotherapeutics, Inc.
-40% -20% 0% 20% 40% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: 21.3% Operating margin (TTM), FY23 Q4: 16.0% Operating margin (TTM), FY24 Q1: 13.5% Operating margin (TTM), FY24 Q2: -38.9% Operating margin (TTM), FY24 Q3: -19.5% Operating margin (TTM), FY24 Q4: 7.3% Operating margin (TTM), FY25 Q1: 7.7% Operating margin (TTM), FY25 Q2: 13.3% Operating margin (TTM), FY25 Q3: 10.3% Operating margin (TTM), FY25 Q4: -10.4% Operating margin (TTM), FY26 Q1: 25.9% Operating margin (TTM), FY26 Q2: 28.9% 28.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 21.3%
FY23 Q4 16.0%
FY24 Q1 13.5%
FY24 Q2 -38.9%
FY24 Q3 -19.5%
FY24 Q4 7.3%
FY25 Q1 7.7%
FY25 Q2 13.3%
FY25 Q3 10.3%
FY25 Q4 -10.4%
FY26 Q1 25.9%
FY26 Q2 28.9%
FCF margin (TTM) Protalix Biotherapeutics, Inc.
-40% -20% 0% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -13.6% FCF margin (TTM), FY23 Q4: -3.8% FCF margin (TTM), FY24 Q1: 7.3% FCF margin (TTM), FY24 Q2: -11.0% FCF margin (TTM), FY24 Q3: 15.7% FCF margin (TTM), FY24 Q4: 13.8% FCF margin (TTM), FY25 Q1: -2.6% FCF margin (TTM), FY25 Q2: -5.6% FCF margin (TTM), FY25 Q3: -18.9% FCF margin (TTM), FY25 Q4: -25.8% FCF margin (TTM), FY26 Q1: 17.0% FCF margin (TTM), FY26 Q2: 9.5% 9.5%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -13.6%
FY23 Q4 -3.8%
FY24 Q1 7.3%
FY24 Q2 -11.0%
FY24 Q3 15.7%
FY24 Q4 13.8%
FY25 Q1 -2.6%
FY25 Q2 -5.6%
FY25 Q3 -18.9%
FY25 Q4 -25.8%
FY26 Q1 17.0%
FY26 Q2 9.5%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0 7 8 35 0 4 4 9 21 34 55 63 38 48 65 53 53 81
Gross profit −3 7 1 26 0 3 4 1 4 25 44 52 22 28 43 29 26 56
EBITDA — — — −8 −31 −25 −21 −31 −33 −18 −9 4 −19 −12 12 5 −4 25
Operating income −32 −30 −37 −12 −34 −29 −24 −33 −35 −19 −11 3 −20 −13 10 4 −6 23
Net income −31 −29 −37 −12 −28 −30 58 −29 −83 −26 −18 −7 −28 −15 8 3 −7 19
Diluted EPS $0.20 −$1.80 −$2.15 −$0.65 −$1.50 −$1.60 $3.05 −$1.45 −$3.19 −$0.90 −$0.61 −$0.22 −$0.62 −$0.31 $0.09 $0.04 −$0.08 $0.24
Growth (year on year)
Revenue — +>999% +26.3% +315.8% −100.0% — +23.9% +110.8% +129.1% +62.4% +59.7% +15.0% −39.0% +24.2% +37.5% −18.5% −1.2% +30.1%
EBITDA — — — — — — — — — — — — −582.2% — — −55.2% −177.3% +159.1%
Operating income — — — — — — — — — — — — −855.1% — — −62.6% −240.4% +183.1%
Net income — — — — — — — −150.6% — — — — — — — −64.7% −325.2% +201.9%
Diluted EPS — — — — — — — −147.5% — — — — — — — −55.6% −300.0% +214.9%
Margins
Gross margin −821.4% — 17.2% 75.4% — 82.1% 83.3% 8.7% 19.0% 72.8% 80.1% 82.7% 57.4% 58.9% 64.9% 54.5% 48.8% 69.2%
EBITDA margin — — — −24.3% — −721.5% −488.1% −338.9% −154.6% −51.5% −16.6% 6.4% −50.4% −25.0% 17.8% 9.8% −7.7% 30.8%
Operating margin <−999% −451.2% −435.6% −34.9% — −810.6% −542.4% −360.5% −163.8% −56.4% −19.6% 4.3% −53.4% −27.3% 16.0% 7.3% −10.4% 28.9%
Net margin <−999% −436.6% −435.6% −33.3% — −849.9% >999% −319.2% −395.9% −77.3% −33.4% −10.4% −71.9% −31.3% 12.7% 5.5% −12.5% 23.5%
Free-cash-flow margin >999% −697.4% −349.1% −4.1% — −853.4% −567.1% −358.2% −52.0% −24.6% −36.5% −42.5% −30.6% −53.8% −3.8% 13.8% −25.8% 9.5%
Cash flow
Cash from operations 44 −38 −24 1 −31 −29 −24 −32 −10 −8 −19 −26 −10 −25 −1 9 −12 10
Capital spending 6 8 6 2 2 1 0 1 1 1 1 1 1 1 1 1 2 2
Free cash flow 38 −46 −29 −1 −33 −30 −25 −33 −11 −8 −20 −27 −12 −26 −2 7 −14 8
Stock-based pay 3 1 1 8 4 1 2 1 0 1 1 3 2 2 3 3 2 2
Free cash flow after stock pay 36 −48 −30 −9 −37 −31 −27 −34 −11 −9 −21 −30 −14 −28 −6 4 −16 6
Balance sheet
Cash 81 36 27 52 86 55 76 63 51 38 18 18 39 17 24 20 15 27
Total debt 0 0 7 5 67 67 68 73 52 48 55 — 28 28 40 0 0 0
Net debt (negative = net cash) −81 −36 −20 −47 −19 13 −9 10 1 10 37 −18 −11 11 17 −20 −15 −27
Diluted shares — 16m 17m 18m 18m 19m 19m 20m 26m 29m 30m 29m 44m 48m 82m 81m 79m 80m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $110m
Short-term assets $92mLonger-term assets $18m
What it owes, and who funded it · $110m
Short-term liabilities $31mLonger-term liabilities $8mShareholders' equity $71m
  • Short-term assets cover short-term liabilities $92m of assets due within a year against $31m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $92m short-term assets against $8m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Protalix Biotherapeutics, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
−4.1%
year over year
R&D spending
24.7%
of revenue
Sales & admin spending
15.7%
of revenue
Days sales outstanding
75 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated PLX AAPG ADCT BCYC ASMB VSTM Median
Revenue, last 12 months $81m $80m $80m $84m $75m $88m $56m
Revenue growth, last 12 months 30.1% −41.4% 3.0% 194.7% 125.1% 26.4% 12.6%
Revenue growth, 3-year average 6.1% — — 49.8% −3.3% 58.4% 13.7%
Revenue growth, latest quarter 27.1% — 2.2% 190.2% 38.9% >999% 10.2%
Gross margin 69.2% 91.5% — — — — 82.9%
Operating margin 28.9% — −125.1% −189.4% −11.8% −182.6% −189.4%
Operating margin, 3-year average 1.1% — −171.7% −581.7% −126.0% −813.6% −363.5%
Net margin 23.5% −216.5% −121.8% −169.8% −0.1% −231.6% −169.8%
Cash from operations / revenue 12.3% −204.5% −128.5% −209.7% −51.4% −185.3% −168.0%
Free-cash-flow margin 9.5% −209.3% −128.5% −211.9% −51.5% −185.3% −162.4%
Free-cash-flow margin, 3-year average −2.3% — −171.3% −539.0% −35.8% — −310.0%
Stock pay / revenue 2.4% 3.6% 12.2% 36.4% 8.9% 11.1% 20.0%
Change in share count −4.1% 17.9% 38.3% 0.6% 50.8% 33.4% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 30.1% 12.6% 70 of 172
Change in growth rate Growth +2.3pp -0.1pp 66 of 172
Gross margin Profitability 69.2% 82.4% 55 of 75
Operating margin Profitability 28.9% -189.4% 15 of 175
Net margin Profitability 23.5% -157.3% 22 of 180
Free-cash-flow margin Cash generation 9.5% -145.4% 34 of 176
Stock pay as % of revenue Cash generation 2.4% 19.2% 12 of 179
Change in share count Balance sheet -4.1% 7.9% 6 of 156
Days sales outstanding Balance sheet 75 days 75 days 51 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $51.8M 98.2% ▼ 2.2%
Licenses and services $942,000 1.8% ▲ 125.4%

From Protalix Biotherapeutics, Inc.'s 10-K filed March 18, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$33.7M
Institutions reporting
102
Shares held vs prior quarter
▼ 14.2%
Positions opened / closed
19 / 16

Top buyers and sellers, Q2 2026: 57 institutions bought and 33 sold ; the biggest buyer was Marshall Wace, LLP (+453K shares) and the biggest seller Mak Capital One LLC (−3.5M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $9.4M 4.0M 28.0% ▲ 11.9%
Renaissance Technologies LLC $2.6M 1.1M 7.6% ▼ 10.5%
State Street Corp $2.3M 984K 6.8% ▲ 1.1%
Geode Capital Management, LLC $2.3M 980K 6.8% ▲ 13.3%
Northern Trust Corp $2.1M 922K 6.4% ▲ 4.2%
Vanguard Portfolio Management LLC $1.2M 511K 3.5% ▲ 18.1%
Stratos Wealth Partners, Ltd. $1.2M 500K 3.5% 0.0%
Dimensional Fund Advisors LP $1.1M 493K 3.4% ▲ 66.2%
Goldman Sachs Group Inc $1.1M 476K 3.3% ▲ 89.4%
Marshall Wace, LLP $1.1M 453K 3.1% New
Citadel Advisors LLC $778,749 334K 2.3% New
Strs Ohio $689,913 296K 2.0% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Protalix Biotherapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $101,360 1 trade by 1 insider, last 12 months Insider sales History → $314 1 trade by 1 insider · 0% under pre-set plans
Net ▲ $101,046 net buying
Insider Date Trade Shares Price Value
Bashan Dror PRESIDENT AND CEO December 19, 2025 Buy 56,000 $1.81 $101,360
Bar-Shalev Amos Director November 18, 2025 Sell 168 $1.87 $314

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 12, 2026 estimated from the company's past filing pattern, not announced

  • August 12, 2026
  • May 13, 2026
  • March 18, 2026
  • November 13, 2025
  • August 14, 2025
  • May 9, 2025

Recent SEC filings

Data status

When each part of this page on Protalix Biotherapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Protalix Biotherapeutics, Inc. in brief

What does Protalix Biotherapeutics, Inc. do?
Protalix Biotherapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Protalix Biotherapeutics, Inc.'s stock ticker?
Protalix Biotherapeutics, Inc. trades under the ticker PLX on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Protalix Biotherapeutics, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Protalix Biotherapeutics, Inc. reported revenue of $80.6M, 30.1% higher than a year earlier, according to its SEC filings.
What is Protalix Biotherapeutics, Inc.'s free cash flow?
Protalix Biotherapeutics, Inc.'s free-cash-flow margin is 9.5% of revenue over the trailing twelve months, ranking 34 of the 176 biotechnology companies we cover.
Who are Protalix Biotherapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Renaissance Technologies LLC and State Street Corp. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Protalix Biotherapeutics, Inc.'s market cap?
On November 2, 2026, Protalix Biotherapeutics, Inc.'s market capitalisation was about $206M, with a price-to-earnings ratio of 10.9 and net debt of -$27.4M. Market figures come from third-party market data and may be delayed.
Who are Protalix Biotherapeutics, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Protalix Biotherapeutics, Inc. are Ascentage Pharma Group International, ADC Therapeutics SA, Bicycle Therapeutics PLC, Assembly Biosciences, Inc. and Verastem, Inc. The side-by-side comparison below sets their revenue, margins and growth against Protalix Biotherapeutics, Inc.'s.
Are insiders buying or selling Protalix Biotherapeutics, Inc. stock?
Over the last 12 months, Protalix Biotherapeutics, Inc.'s directors and officers reported 1 open-market purchases and 1 sales on Form 4. The insider trading page charts every trade.
When is Protalix Biotherapeutics, Inc.'s next earnings date?
Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Protalix Biotherapeutics, Inc. announces its own schedule.